Welcome to this Distinguished Guest Lecture titled “RNA-based therapeutics and personalized neoantigen cancer vaccines”.
Dr. Özlem Türeci, Chief Medical Officer, BioNTech and Professor, Mainz University Medical Ctr & Helmholtz Institute for Translational Oncology will give a lecture titled “RNA-based therapeutics and personalized neoantigen cancer vaccines” at Kaare Norum Auditorium, Radiumhospitalet/Oslo Cancer Cluster Innovation Park on 16th November at 14:00.
The lecture is organised by the Institute for Cancer Research, Oslo University Hospital, CoE PRIMA, University of Oslo and Norwegian Society for Immunology.
Registration: The event requires registration. Please fill out this online registration form to secure your attendance.
“When the pandemic broke in early 2020, mRNA companies acted quickly to develop COVID-19 vaccines. BioNTech and Moderna chose to use mRNA with modified bases building on the discoveries by Karikó and Weissmann. BioNTech, with Uğur Şahin and Özlem Türeci in the lead, worked in partnership with Pfizer.”
Learn more about Dr. Tureci’s research into cancer vaccines in the following paper published in Nature (June 2023): Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. It was cited in several Norwegian media outlets, including the national newspapers Verdens Gang and Dagens Medisin (both links in Norwegian).
Please note. Dr. Tureci will also give a talk at 18:00 in the Norwegian Academy of Science and Letters titled “Vaccines: mRNA vaccine technology – COVID-19, Cancer & beyond”. You can read more about the second talk on the Norwegian Science Academy’s website (NB Registration by email to Line Therese Nævestad: firstname.lastname@example.org).